Thermo Fisher Scientific Inc. (TMO)
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Thermo Fisher has outperformed the market with a 420%+ return over the past decade, but its current valuation is high. The company's recent results show mixed performance, with slight revenue decline, but improved earnings-per-share and raised 2024 guidance. Despite strong growth prospects and market tailwinds, the stock's high valuation and low dividend yield make it a hold for now.
Exclusive: Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript
Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.
